These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36820316)

  • 21.
    Wang W; Huang S; Zou C; Ding Y; Wang H; Pu S; Liao Y; Du H; Wang D; Chen L; Niu S
    Front Cell Infect Microbiol; 2021; 11():755763. PubMed ID: 34778107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.
    Poirel L; Naas T; Nicolas D; Collet L; Bellais S; Cavallo JD; Nordmann P
    Antimicrob Agents Chemother; 2000 Apr; 44(4):891-7. PubMed ID: 10722487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
    Sadek M; Juhas M; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A practical laboratory method to determine ceftazidime-avibactam-aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing Enterobacterales infection.
    Rawson TM; Brzeska-Trafny I; Maxfield R; Almeida M; Gilchrist M; Gonzalo X; Moore LS; Donaldson H; Davies F
    J Glob Antimicrob Resist; 2022 Jun; 29():558-562. PubMed ID: 35131508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoroquinolone resistance in carbapenem-resistant Elizabethkingia anophelis: phenotypic and genotypic characteristics of clinical isolates with topoisomerase mutations and comparative genomic analysis.
    Jian MJ; Cheng YH; Chung HY; Cheng YH; Yang HY; Hsu CS; Perng CL; Shang HS
    J Antimicrob Chemother; 2019 Jun; 74(6):1503-1510. PubMed ID: 30830171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
    Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
    J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Lin JN; Lai CH; Yang CH; Huang YH
    Microorganisms; 2019 Aug; 7(9):. PubMed ID: 31466280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China.
    Zhang B; Zhu Z; Jia W; Qu F; Huang B; Shan B; Yu H; Tang Y; Chen L; Du H
    Int J Infect Dis; 2020 Aug; 97():11-18. PubMed ID: 32473388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.
    Wang Q; Jin L; Sun S; Yin Y; Wang R; Chen F; Wang X; Zhang Y; Hou J; Zhang Y; Zhang Z; Luo L; Guo Z; Li Z; Lin X; Bi L; Wang H
    Microbiol Spectr; 2022 Jun; 10(3):e0267021. PubMed ID: 35481835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends of β-Lactamase Occurrence Among
    Castanheira M; Kimbrough JH; DeVries S; Mendes RE; Sader HS
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad038. PubMed ID: 36776778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
    Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
    Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
    Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae.
    Maraki S; Mavromanolaki VE; Moraitis P; Stafylaki D; Kasimati A; Magkafouraki E; Scoulica E
    Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1755-1759. PubMed ID: 33595756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
    Rossolini GM; Stone GG
    Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against
    Liao CH; Lee NY; Tang HJ; Lee SS; Lin CF; Lu PL; Wu JJ; Ko WC; Lee WS; Hsueh PR
    Infect Drug Resist; 2019; 12():545-552. PubMed ID: 30881060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study.
    La Bella G; Lopizzo T; Lupo L; Angarano R; Curci A; Manti B; La Salandra G; Mosca A; De Nittis R; Arena F
    J Glob Antimicrob Resist; 2022 Dec; 31():236-238. PubMed ID: 36208851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.